Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes

다국어 초록 (Multilingual Abstract)

Purpose: To investigate the efficacy of aflibercept for the treatment of diabetic macular edema via a treat-and-extend regimen.
Methods: This prospective, single-center, open-label, interventional study involved 30 patients with a best-corrected visualacuity (BCVA) ≤0.6 and a central retinal thickness (CRT) ≥300 μm. The enrolled eyes each received a monthly intravitreal afliberceptinjection until the CRT decreased below 300 μm, upon which the administration interval was extended for 1 monthuntil the CRT once again increased to ≥300 μm. Main outcome measures were median BCVA and CRT at 6 and 12 monthsafter initiation of treatment via last observation carried forward analysis, the median number of injections over the 12months, and the effects on the diabetic retinopathy severity scale (DRSS) score of the patients who completed the 12-monthfollow-up period.
Results: Of the 30 enrolled patients, 29 and 25 respectively completed the 6- and 12-month follow-up examinations. Frombaseline to 6 and 12 months after treatment initiation, the median BCVA (logarithm of the minimum angle of resolution) significantlyimproved from 0.52 to 0.30 and 0.35, respectively, and the median CRT significantly decreased from 439.5 to 268.5and 249.0 μm, respectively. The median number of injections over the 12-month follow-up period was 6.0. Compared tobaseline, the DRSS score at 12 months was improved by 2 steps in 16% of patients; in no cases did the DRSS score worsen orimprove by three steps or more.
Conclusions: When administered in a treat-and-extend regimen, aflibercept is an effective treatment option for diabeticmacular edema.

참고문헌 (Reference)

1 Murata T, "Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels" 27 : 48-52, 1995

2 Freund KB, "Treat-andextend regimens with anti-vegf agents in retinal diseases : a literature review and consensus recommendations" 35 : 1489-1506, 2015

3 Silva R, "Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration : results with ranibizumab from the TREND Study" 125 : 57-65, 2018

4 Nguyen QD, "Ranibizumab for diabetic macular edema : results from 2 phase III randomized trials : RISE and RIDE" 119 : 789-801, 2012

5 Prunte C, "Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema:the RETAIN study" 100 : 787-795, 2016

6 Payne JF, "Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema : TREX-DME 1 year outcomes" 124 : 74-81, 2017

7 Pieramici D, "Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies" 2 : 558-566, 2018

8 Kim LN, "Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration" 36 : 1418-1431, 2016

9 Ip MS, "Long-term effects of ranibizumab on diabetic retinopathy severity and progression" 130 : 1145-1152, 2012

10 Korobelnik JF, "Intravitreal aflibercept for diabetic macular edema" 121 : 2247-2254, 2014

11 Staurenghi G, "Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies" 102 : 954-958, 2018

12 "Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group" 98 : 786-806, 1991

13 Lanzetta P, "Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases" 255 : 1259-1273, 2017

14 Mitchell P, "Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies" 2 : 988-996, 2018

15 Zhang Y, "Effects of aflibercept for neovascular age-related macular degeneration : a systematic review and meta-analysis of observational comparative studies" 58 : 5616-5627, 2017

16 Hirano T, "Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation" 61 : 51-60, 2017

17 Sugimoto M, "Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan" 10 : 475-483, 2019

18 Ashraf M, "Age-related macular degeneration : using morphological predictors to modify current treatment protocols" 96 : 120-133, 2018

19 Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema" 372 : 1193-1203, 2015

20 Stewart MW, "Aflibercept(VEGF Trap-eye) : the newest anti-VEGF drug" 96 : 1157-1158, 2012

21 Kanda A, "Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy" 5 : 17946-, 2015

22 Avitabile T, "Aflibercept in the treatment of diabetic macular edema : a review and consensus paper" 27 : 627-639, 2017

23 Chin-Yee D, "A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration" 100 : 914-917, 2016